Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
A Bank of England Market Participants Survey finds investors anticipate the central bank will reduce its Bank Rate from 3.75% to 3.0% by the March 2027 meeting. The survey, conducted Jan. 21-23 with 92 respondents, also left the median forecast for 12-month quantitative tightening unchanged at 50 billion pounds and lifted the 10-year gilt year-end …
Mizuho raised its price target on WEC Energy Group to $121 from $117 and retained an Outperform rating, citing expanded corporate demand and a heavier capital program. The utility reported full-year 2025 EPS modestly above estimates, set a 2026 guidance range, and flagged multi-state regulatory events and a sizeable customer-driven capex increase. …
Mizuho lowered its 12-month price target for O’Reilly Automotive to $105.00 from $110.00 while retaining an Outperform rating, following the company’s recent earnings call. The bank adjusted its financial models to reflect management commentary about rising self-insurance and other operating expenses, even as revenue growth and gross margins remain…
Wells Fargo raised its price objective on XPO to $205 from $147 and reiterated an Overweight rating, pointing to an improving operating ratio and conservative 2026 assumptions. The stock has jumped sharply in recent days and now trades near its 52-week high, while multiple other brokerages have also increased targets amid better-than-expected resul…
Benchmark has maintained its Buy rating and $705.00 price target on Strategy (NASDAQ:MSTR), basing the valuation on a multi-part sum-of-the-parts analysis through year-end 2026 that incorporates bitcoin holdings, a 10x multiple of estimated bitcoin dollar gains for fiscal 2026, and the projected value of the company’s software operations. The decis…
Wells Fargo lowered its price target on OneMain Holdings (NYSE: OMF) to $70 from $75 but kept an Equal Weight rating, citing persistent inflation and a cloudy macroeconomic outlook that have prompted OneMain to retain conservative underwriting. The stock trades well below the revised target, and the company’s financial metrics remain constructive, …
Stephens Inc. highlights three technology companies it views as particularly well-positioned to benefit from an anticipated acceleration in AI adoption and a recovery in corporate IT budgets entering 2026. The research note emphasizes enterprise software, identity-security platforms and large-scale payments infrastructure firms whose business model…
On Feb. 6, Cboe Global Markets reported a substantial increase in fourth-quarter profit, driven by higher options trading volumes amid a period of elevated market volatility. The exchange saw a marked rise in net revenue from options and reported increased net income per share year over year. At the same time, Cboe is refocusing its business by exi…
Jefferies analyst Brent Thill warns that Palantir's lofty trading multiple leaves the stock vulnerable to further declines even after a significant pullback this year. While Palantir reported strong fourth-quarter results and improving fundamentals, Jefferies says valuation compression may outweigh those gains and maintained an Underperform rating …
Otis Worldwide has pulled back from its 52-week high into a zone that restores upside skew for long-term investors. The core service business generates steady free cash flow ($1.323B trailing), the company just raised its quarterly payout to $0.42, and technicals show constructive momentum. Valuation is not deeply cheap - EV/EBITDA ~21 and P/E ~26 …
H.C. Wainwright resumed coverage of NovaBridge Biosciences with a Buy rating and raised its price target to $9 from $7 following encouraging Phase 1b topline results for givastomig in combination with nivolumab and chemotherapy in first-line HER2-negative metastatic gastric cancer. The data show high objective response rates across dosing cohorts w…
H.C. Wainwright increased its price objective for Imunon (NASDAQ: IMNN) to $25 from $14 while retaining a Buy rating, citing the company’s shift to concentrate resources on its Phase 3 OVATION 3 study in newly diagnosed advanced ovarian cancer patients. The move follows a strategic restructuring to reduce operating expenses, a December registered d…
Stephens reduced its price target for Affirm Holdings Inc. to $65 from $75 and kept an Equal Weight rating, attributing the move to compression in peer multiples even after Affirm delivered fiscal Q2 results that beat estimates and lifted fiscal 2026 guidance. Other broker moves were mixed, with UBS, Needham and Citizens issuing varied targets and …
Cantor Fitzgerald reduced its price target on Iris Energy (IREN) to $82 from $136 but maintained an Overweight rating, following a quarter that saw revenue and adjusted EBITDA decline as the company transitions capacity from Bitcoin mining to AI compute. Management has secured major financing for GPU procurement and reiterated multi-billion-dollar …
Wells Fargo analyst Mohit Bansal raised his price target on Bristol-Myers Squibb to $60 from $55 and kept an Equal Weight rating, citing upside to 2026 guidance and a pipeline of readouts. The stock trades near the new target and recent quarterly results beat expectations, while competing clinical data attracted additional analyst endorsement.
UBS Global Research upgraded Orior AG to a 'neutral' rating from 'sell', arguing that the market has already incorporated the company's soft operating momentum and elevated leverage. The bank lowered its 12-month price target to CHF11.50 from CHF12, adjusted earnings forecasts, and flagged a possible Culinor divestment as a partial balance-sheet mi…
Dave Inc. reported preliminary fourth-quarter results that outperformed analyst expectations, sending the stock up 16% in morning trading. The company recorded $164 million in Q4 revenue, a 62% year-over-year increase and its third straight quarter above 60% growth. Preliminary Adjusted EBITDA and full-year 2025 results also topped prior guidance, …
Bank of America says a 25% year-to-date decline in the software sector has produced selective buying opportunities. Analyst Koji Ikeda singled out Snowflake, MongoDB, Datadog and JFrog as the first candidates to recover, citing each company’s positioning around AI data, observability, and binary management.
Canaccord Genuity reaffirmed its Buy rating and $10.00 price objective on Peloton Interactive after the company reported fiscal second-quarter 2026 results on February 5. Peloton missed revenue expectations, posted a wider-than-expected per-share loss, and saw a year-over-year decline in active subscribers even as retention improved. Analysts point…
Oppenheimer increased its price target for Acadia Pharmaceuticals (ACAD) to $23 from $21 and retained an Outperform rating after discussions with management about the company's longer-term revenue plan, which targets roughly $1.7 billion in annual sales by 2028. The outlook factors in continued Nuplazid growth, accelerated Daybue uptake with a new …
Stifel raised its price objective on MGM Resorts to $50 from $45 and kept a Buy rating, citing a pathway for Las Vegas Strip EBITDA growth in the second half of 2026 and a 2027 sum-of-the-parts valuation underpinning the updated target. The stock trades well below the new target and carries a high reported P/E; recent quarterly results exceeded exp…
Guggenheim lowered its price target on Atlassian (TEAM) to $190 from $225 but maintained a Buy rating. The move follows a quarter in which Atlassian delivered a "clean Cloud beat and raise," with significant product and financial metrics highlighted by the firm even as the stock trades near its 52-week low. Canaccord Genuity also trimmed its target…
Canaccord Genuity has reaffirmed a Hold rating and a $150.00 price target on Illumina (ILMN) after the company released fourth-quarter 2025 results that matched prior guidance and analyst expectations. Strength outside China and ongoing adoption of the NovaSeq X platform helped drive outperformance in consumables, while management set 2026 revenue …
DA Davidson increased its price target on Barrick Gold Corp. to $60 from $53 while retaining a Buy recommendation following a second-quarter performance that topped consensus across revenue, EBIT and EBITDA. The firm highlights accelerating retail-versus-spot spreads that began widening late in Q2 2026 and continued into Q3 2026, strong liquidity a…
Needham raised its 12-month price target for Microchip Technology (NASDAQ:MCHP) to $84.00 from $77.00 while reaffirming a Buy rating, citing an improving demand environment and better-than-expected margin performance. The new target implies only modest upside from the shares' recent trading level, which sits near a 52-week high after strong 12-mont…
